P2x7 receptors: Role in bone cell formation and function

Journal of Molecular Endocrinology

Volumn 54, Issue 2, 2015, Pages R75-R88

  Agrawal, Ankita ^a   Gartland, Alison ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Apoptosis; Bone; Cancer; Osteoblast; Osteoclast; P2X7

Indexed keywords

PURINERGIC P2 RECEPTOR; ADENOSINE TRIPHOSPHATE; PURINERGIC P2X7 RECEPTOR;

APOPTOSIS; BONE CELL; BONE MINERALIZATION; CELL FUNCTION; CELL SURVIVAL; GENETIC VARIABILITY; HUMAN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; BONE TUMOR; CYTOLOGY; GENETICS; METABOLISM; OSTEOCYTE; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOSINE TRIPHOSPHATE; ANIMALS; BONE NEOPLASMS; HUMANS; OSTEOCYTES; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PURINERGIC P2X7; SIGNAL TRANSDUCTION;

EID: 84929078404     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-14-0226     Document Type: Review

References (129)

1. Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, MinelliM, Wieckowski MR, Pinton P, Rizzuto R & Di Virgilio F 2005 Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Molecular Biology of the Cell 16 3260–3272. (doi:10.1091/mbc.E04- 11-1025)
2. Adinolfi E, Callegari MG, Cirillo M, Pinton P, Giorgi C, Cavagna D, Rizzuto R & Di Virgilio F 2009 Expression of the P2X7 receptor increases the Ca2C content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis. Journal of Biological Chemistry 284 10120–10128. (doi:10.1074/jbc.M805805200)
3. Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P, Callegari MG, Sandona D, Markwardt F, Schmalzing G et al. 2010 Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB Journal 24 3393–3404. (doi:10.1096/fj.09-153601)
4. Adinolfi E, Amoroso F & Giuliani AL 2012a P2X7 receptor function in bone-related cancer. Journal of Osteoporosis 2012 637-863. (doi:10.1155/ 2012/637863)
5. Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, Bianchi G, Kroemer G, Pistoia V & Di Virgilio F 2012b Expression of P2X7 receptor increases in vivo tumor growth. Cancer Research 72 2957–2969. (doi:10.1158/0008-5472.CAN-11-1947)
6. Adriouch S, Dox C, Welge V, Seman M, Koch-Nolte F & Haag F 2002 Cutting edge: a natural P451L mutation in the cytoplasmic domain impairs the function of the mouse P2X7 receptor. Journal of Immunology 169 4108–4112. (doi:10.4049/jimmunol.169.8.4108)
7. Agrawal A & Gartland A 2011 Expression of NFATc1 is inducible by P2X7 receptor activation in human osteoclasts. In European Calcified Tissue Society, International Bone and Mineral Society, Poster Presentation, p S126. Athens: Bone.
8. Agrawal A, Buckley KA, Bowers K, Furber M, Gallagher JA & Gartland A 2010 The effects of P2X7 receptor antagonists on the formation and function of human osteoclasts in vitro. Purinergic Signalling 6 307–315. (doi:10.1007/s11302-010-9181-z)
9. Alqallaf SM, Evans BA & Kidd EJ 2009 Atypical P2X receptor pharmacology in two human osteoblast-like cell lines. British Journal of Pharmacology 156 1124–1135. (doi:10.1111/j.1476-5381.2009.00119.x)
10. Al-Shukaili A, Al-Kaabi J, Hassan B, Al-Araimi T, Al-Tobi M, Al-Kindi M, Al-Maniri A, Al-Gheilani A & Al-Ansari A 2011 P2X7 receptor gene polymorphism analysis in rheumatoid arthritis. International Journal of Immunogenetics 38 389–396. (doi:10.1111/j.1744-313X.2011.01019.x)
11. Armstrong S, Pereverzev A, Dixon SJ & Sims SM 2009 Activation of P2X7 receptors causes isoform-specific translocation of protein kinase C in osteoclasts. Journal of Cell Science 122 136–144. (doi:10.1242/jcs. 031534)
12. Barbosa CM, Leon CM, Nogueira-Pedro A, Wasinsk F, Araujo RC, Miranda A, Ferreira AT & Paredes-Gamero EJ 2011 Differentiation of hematopoietic stem cell and myeloid populations by ATP is modulated by cytokines. Cell Death & Disease 2 e165. (doi:10.1038/cddis.2011.49)
13. Barrera NP, Ormond SJ, Henderson RM, Murrell-Lagnado RD & Edwardson JM 2005 Atomic force microscopy imaging demonstrates that P2X2 receptors are trimers but that P2X6 receptor subunits do not oligomerize. Journal of Biological Chemistry 280 10759–10765. (doi:10.1074/jbc.M412265200)
14. Bartlett R, Stokes L & Sluyter R 2014 The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacological Reviews 66 638–675. (doi:10.1124/pr.113.008003)
15. Bender E, Buist A, Jurzak M, Langlois X, Baggerman G, Verhasselt P, Ercken M, Guo HQ, Wintmolders C, Van den Wyngaert I et al. 2002 Characterization of an orphan G protein-coupled receptor localized in the dorsal root ganglia reveals adenine as a signaling molecule. PNAS 99 8573–8578. (doi:10.1073/pnas.122016499)
16. Biver G,Wang N, Gartland A,Orriss I, Arnett TR, Boeynaems JM & Robaye B 2013 Role of the P2Y13 receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes. Stem Cells 31 2747–2758. (doi:10.1002/stem.1411)
17. Brandao-Burch A, Key ML, Patel JJ, Arnett TR & Orriss IR 2012 The P2X7 receptor is an important regulator of extracellular ATP levels. Frontiers in Endocrinology 3 41. (doi:10.3389/fendo.2012.00041)
18. Browne LE, Jiang LH & North RA 2010 New structure enlivens interest in P2X receptors. Trends in Pharmacological Sciences 31 229–237. (doi:10.1016/j.tips.2010.02.004)
19. Buckley KA, Hipskind RA, Gartland A, Bowler WB & Gallagher JA 2002 Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kB ligand. Bone 31 582–590. (doi:10.1016/S8756-3282(02)00877-3)
20. Burnstock G 2007 Purine and pyrimidine receptors. Cellular and Molecular Life Sciences 64 1471–1483. (doi:10.1007/s00018-007-6497-0)
21. Burnstock G 2013 Introduction and perspective, historical note. Frontiers in Cellular Neuroscience 7 227. (doi:10.3389/fncel.2013.00227)
22. Burnstock G 2014a Purinergic signalling in the gastrointestinal tract and related organs in health and disease. Purinergic Signalling 10 3–50. (doi:10.1007/s11302-013-9397-9)
23. Burnstock G 2014b Purinergic signalling in the urinary tract in health and disease. Purinergic Signalling 10 103–155. (doi:10.1007/ s11302-013-9395-y)
24. Burnstock G 2014c Purinergic signalling in the reproductive system in health and disease. Purinergic Signalling 10 157–187. (doi:10.1007/ s11302-013-9399-7)
25. Burnstock G 2014d Purinergic signalling in endocrine organs. Purinergic Signalling 10 189–231. (doi:10.1007/s11302-013-9396-x)
26. Burnstock G & Verkhratsky A 2009 Evolutionary origins of the purinergic signalling system. Acta Physiologica 195 415–447. (doi:10.1111/ j.1748-1716.2009.01957.x)
27. Burnstock G, Evans LC & Bailey MA 2014a Purinergic signalling in the kidney in health and disease. Purinergic Signalling 10 71–101. (doi:10.1007/s11302-013-9400-5)
28. Burnstock G, Vaughn B & Robson SC 2014b Purinergic signalling in the liver in health and disease. Purinergic Signalling 10 51–70. (doi:10.1007/ s11302-013-9398-8)
29. Cherian PP, Siller-Jackson AJ, Gu S, Wang X, Bonewald LF, Sprague E & Jiang JX 2005 Mechanical strain opens connexin 43 hemichannels in osteocytes: a novel mechanism for the release of prostaglandin. Molecular Biology of the Cell 16 3100–3106. (doi:10.1091/mbc. E04-10-0912)
30. Chessell IP, Hatcher JP, Bountra C, Michel AD,Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL et al. 2005 Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114 386–396. (doi:10.1016/j.pain.2005.01.002)
31. Di Virgilio F 2012 Purines, purinergic receptors, and cancer. Cancer Research 72 5441–5447. (doi:10.1158/0008-5472.CAN-12-1600)
32. Di Virgilio F, Falzoni S, Chiozzi P, Sanz JM, Ferrari D & Buell GN 1999 ATP receptors and giant cell formation. Journal of Leukocyte Biology 66 723–726.
33. Di Virgilio F, Ferrari D & Adinolfi E 2009 P2X(7): a growth-promoting receptor-implications for cancer. Purinergic Signalling 5 251–256. (doi:10.1007/s11302-009-9145-3)
34. Donnelly-Roberts DL, Namovic MT, Han P & Jarvis MF 2009 Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. British Journal of Pharmacology 157 1203–1214. (doi:10.1111/j.1476-5381.2009.00233.x)
35. Farrell AW, Gadeock S, Pupovac A, Wang B, Jalilian I, RansonM& Sluyter R 2010 P2X7 receptor activation induces cell death and CD23 shedding in human RPMI 8226 multiple myeloma cells. Biochimica et Biophysica Acta 1800 1173–1182. (doi:10.1016/j.bbagen.2010.07.001)
36. Ferrari D, Stroh C & Schulze-Osthoff K 1999 P2X7/P2Z purinoreceptormediated activation of transcription factor NFAT in microglial cells. Journal of Biological Chemistry 274 13205–13210. (doi:10.1074/jbc.274.19.13205)
37. Fountain SJ, Parkinson K, Young MT, Cao L, Thompson CR & North RA 2007 An intracellular P2X receptor required for osmoregulation in Dictyostelium discoideum. Nature 448 200–203. (doi:10.1038/nature05926)
38. Gartland A, Hipskind RA, Gallagher JA & Bowler WB 2001 Expression of a P2X7 receptor by a subpopulation of human osteoblasts. Journal of Bone and Mineral Research 16 846–856. (doi:10.1359/jbmr.2001.16.5.846)
39. Gartland A, Buckley KA, Bowler WB & Gallagher JA 2003a Blockade of the pore-forming P2X7 receptor inhibits formation of multinucleated human osteoclasts in vitro. Calcified Tissue International 73 361–369. (doi:10.1007/s00223-002-2098-y)
40. Gartland A, Buckley KA, Hipskind RA, Perry MJ, Tobias JH, Buell G, Chessell I, Bowler WB & Gallagher JA 2003b Multinucleated osteoclast formation in vivo and in vitro by P2X7 receptor-deficient mice. Critical Reviews in Eukaryotic Gene Expression 13 243–253. (doi:10.1615/CritRevEukaryotGeneExpr.v13.i24.150)
41. Gartland A, Orriss IR, Rumney RM, Bond AP, Arnett T & Gallagher JA 2012a Purinergic signalling in osteoblasts. Frontiers in Bioscience 17 16–29. (doi:10.2741/3912)
42. Gartland A, Skarratt KK,Hocking LJ, Parsons C, Stokes L, JorgensenNR, Fraser WD, ReidDM, Gallagher JA&Wiley JS 2012b Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bonemineral density and accelerated bone loss in post-menopausalwomen. European Journal of Human Genetics 20 559–564. (doi:10.1038/ejhg.2011.245)
43. Gavala ML, Hill LM, Lenertz LY, Karta MR & Bertics PJ 2010 Activation of the transcription factor FosB/activating protein-1 (AP-1) is a prominent downstream signal of the extracellular nucleotide receptor P2RX7 in monocytic and osteoblastic cells. Journal of Biological Chemistry 285 34288–34298. (doi:10.1074/jbc.M110.142091)
44. Genetos DC, Karin NJ, Geist DJ, Donahue HJ & Duncan RL 2011 Purinergic signaling is required for fluid shear stress-induced NF-kB translocation in osteoblasts. Experimental Cell Research 317 737–744. (doi:10.1016/j.yexcr.2011.01.007)
45. Giuliani AL, Colognesi D, Ricco T, Roncato C, Capece M, Amoroso F, Wang QG, De Marchi E, Gartland A, Di Virgilio F et al. 2014 Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma. PLoS ONE 9 e107224. (doi:10.1371/journal.pone.0107224)
46. Gorodeski GI 2009 P2X7-mediated chemoprevention of epithelial cancers. Expert Opinion on Therapeutic Targets 13 1313–1332. (doi:10.1517/14728220903277249)
47. Gorzalka S, Vittori S, Volpini R, Cristalli G, von Kugelgen I & Muller CE 2005 Evidence for the functional expression and pharmacological characterization of adenine receptors in native cells and tissues. Molecular Pharmacology 67 955–964. (doi:10.1124/mol.104.006601)
48. Greig AV, Linge C, Healy V, Lim P, Clayton E, Rustin MH, McGrouther DA & Burnstock G 2003 Expression of purinergic receptors in nonmelanoma skin cancers and their functional roles in A431 cells. Journal of Investigative Dermatology 121 315–327. (doi:10.1046/j.1523-1747.2003.12379.x)
49. Grol MW, Zelner I& Dixon SJ 2012 P2X(7)-mediated calciuminflux triggers a sustained, PI3K-dependent increase in metabolic acid production by osteoblast-like cells. American Journal of Physiology. Endocrinology and Metabolism 302 E561–E575. (doi:10.1152/ajpendo.00209.2011)
50. Hansen RR, Nielsen CK, Nasser A, Thomsen SI, Eghorn LF, Pham Y, Schulenburg C, Syberg S, Ding M, Stojilkovic SS et al. 2011 P2X7 receptor-deficient mice are susceptible to bone cancer pain. Pain 152 1766–1776. (doi:10.1016/j.pain.2011.03.024)
51. Hazama R, Qu X, Yokoyama K, Tanaka C, Kinoshita E, He J, Takahashi S, Tohyama K, Yamamura H & Tohyama Y 2009 ATP-induced osteoclast function: the formation of sealing-zone like structure and the secretion of lytic granules via microtubule-deacetylation under the control of Syk. Genes to Cells 14 871–884. (doi:10.1111/j.1365-2443.2009.01317.x)
52. Hoebertz A, Townsend-Nicholson A, Glass R, Burnstock G & Arnett TR 2000 Expression of P2 receptors in bone and cultured bone cells. Bone 27 503–510. (doi:10.1016/S8756-3282(00)00351-3)
53. Hwang YS, Ma GT, Park KK & Chung WY 2013 Lysophosphatidic acid stimulates osteoclast fusion through OC-STAMP and P2X7 receptor signaling. Journal of Bone and Mineral Metabolism 32 110–122. (doi:10.1007/s00774-013-0470-9)
54. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A & Bravo R 1997 Osteopetrosis in mice lacking NF-kB1 and NF-kB2. Nature Medicine 3 1285–1289. (doi:10.1038/nm1197-1285)
55. Jiang LH, Mackenzie AB, North RA & Surprenant A 2000 Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors. Molecular Pharmacology 58 82–88. (doi:1124/mol.58.1.82)
56. Jorgensen NR, Henriksen Z, Sorensen OH, Eriksen EF, Civitelli R & Steinberg TH 2002 Intercellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X7 receptors. Journal of Biological Chemistry 277 7574–7580. (doi:10.1074/jbc.M104608200)
57. Jorgensen NR, Husted LB, Skarratt KK, Stokes L, Tofteng CL, Kvist T, Jensen JE, Eiken P, Brixen K, Fuller S et al. 2012 Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. European Journal of Human Genetics 20 675–681. (doi:10.1038/ejhg.2011.253)
58. Kaczmarek-Hajek K, Lorinczi E, Hausmann R& Nicke A 2012 Molecular and functional properties of P2X receptors – recent progress and persisting challenges. Purinergic Signalling 8 375–417. (doi:10.1007/s11302-012-9314-7)
59. Ke HZ ,Qi H ,Weidema AF , Zhang Q , Panupinthu N , Crawford DT ,Grasser WA , Paralkar VM , Li M , Audoly LP et al. 2003 Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Molecular Endocrinology 17 1356–1367. (doi:10.1210/me.2003-0021)
60. Khakh BS & North RA 2006 P2X receptors as cell-surface ATP sensors in health and disease. Nature 442 527–532. (doi:10.1038/nature04886)
61. Khakh BS, Bao XR, Labarca C & Lester HA 1999 Neuronal P2X transmittergated cation channels change their ion selectivity in seconds. Nature Neuroscience 2 322–330. (doi:10.1038/7233)
62. Korcok J, Raimundo LN, Ke HZ, Sims SM & Dixon SJ 2004 Extracellular nucleotides act through P2X7 receptors to activate NF-kB in osteoclasts. Journal of Bone and Mineral Research 19 642–651. (doi:10.1359/JBMR.040108)
63. Koshimizu TA, Van Goor F, Tomic M, Wong AO, Tanoue A, Tsujimoto G & Stojilkovic SS 2000 Characterization of calcium signaling by purinergic receptor-channels expressed in excitable cells. Molecular Pharmacology 58 936–945. (doi:10.1124/mol.58.5.936)
64. Kuehnel MP, Rybin V, Anand PK, Anes E & Griffiths G 2009 Lipids regulate P2X7-receptor-dependent actin assembly by phagosomes via ADP translocation and ATP synthesis in the phagosome lumen. Journal of Cell Science 122 499–504. (doi:10.1242/jcs.034199)
65. von Kugelgen I, Schiedel AC, Hoffmann K, Alsdorf BB, Abdelrahman A & Muller CE 2008 Cloning and functional expression of a novel Gi protein-coupled receptor for adenine from mouse brain. Molecular Pharmacology 73 469–477. (doi:10.1124/mol.107.037069)
66. Lemoli RM, Ferrari D, Fogli M, Rossi L, Pizzirani C, Forchap S, Chiozzi P, Vaselli D, Bertolini F, Foutz T et al. 2004 Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. Blood 104 1662–1670. (doi:10.1182/blood-2004-03-0834)
67. Li J, Liu D, Ke HZ, Duncan RL & Turner CH 2005 The P2X7 nucleotide receptor mediates skeletal mechanotransduction. Journal of Biological Chemistry 280 42952–42959. (doi:10.1074/jbc.M506415200)
68. Li M, Thompson DD & Paralkar VM 2007 Prostaglandin E(2) receptors in bone formation. International Orthopaedics 31 767–772. (doi:10.1007/s00264-007-0406-x)
69. Li J, Meyer R, Duncan RL & Turner CH 2009 P2X7 nucleotide receptor plays an important role in callus remodeling during fracture repair. Calcified Tissue International 84 405–412. (doi:10.1007/s00223-009-9237-7)
70. Liu D, Genetos DC, Shao Y, Geist DJ, Li J, Ke HZ, Turner CH & Duncan RL 2008 Activation of extracellular-signal regulated kinase (ERK1/2) by fluid shear is Ca(2C)- and ATP-dependent in MC3T3-E1 osteoblasts. Bone 42 644–652. (doi:10.1016/j.bone.2007.09.058)
71. Ludlow MJ, Durai L & Ennion SJ 2009 Functional characterization of intracellular Dictyostelium discoideum P2X receptors. Journal of Biological Chemistry 284 35227–35239. (doi:10.1074/jbc.M109.045674)
72. Masin M, Young C, Lim K, Barnes SJ, Xu XJ, Marschall V, Brutkowski W, Mooney ER, Gorecki DC & Murrell-Lagnado R 2012 Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts. British Journal of Pharmacology 165 978–993. (doi:10.1111/j.1476-5381.2011.01624.x)
73. McBeath R, Pirone DM, Nelson CM, Bhadriraju K & Chen CS 2004 Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Developmental Cell 6 483–495. (doi:10.1016/S1534-5807(04)00075-9)
74. Mio K, Kubo Y, Ogura T, Yamamoto T & Sato C 2005 Visualization of the trimeric P2X2 receptor with a crown-capped extracellular domain. Biochemical and Biophysical Research Communications 337 998–1005. (doi:10.1016/j.bbrc.2005.09.141)
75. Miyazaki T, Iwasawa M, Nakashima T, Mori S, Shigemoto K, Nakamura H, Katagiri H, Takayanagi H & Tanaka S 2012 Intracellular and extracellular ATP coordinately regulate the inverse correlation between osteoclast survival and bone resorption. Journal of Biological Chemistry 287 37808–37823. (doi:10.1074/jbc.M112.385369)
76. Naemsch LN, Dixon SJ & Sims SM 2001 Activity-dependent development of P2X7 current and Ca2C entry in rabbit osteoclasts. Journal of Biological Chemistry 276 39107–39114. (doi:10.1074/jbc.M105881200)
77. Nakamura E, Uezono Y, Narusawa K, Shibuya I, Oishi Y, Tanaka M, Yanagihara N, Nakamura T & Izumi F 2000 ATP activates DNA synthesis by acting on P2X receptors in human osteoblast-like MG-63 cells. American Journal of Physiology. Cell Physiology 279 C510–C519.
78. Nicke A, Baumert HG, Rettinger J, Eichele A, Lambrecht G, Mutschler E & Schmalzing G 1998 P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO Journal 17 3016–3028. (doi:10.1093/emboj/17.11.3016)
79. Nicke A, Kuan YH, Masin M, Rettinger J, Marquez-Klaka B, Bender O, Gorecki DC, Murrell-Lagnado RD & Soto F 2009 A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. Journal of Biological Chemistry 284 25813–25822. (doi:10.1074/jbc.M109.033134)
80. Noronha-Matos JB, Coimbra J, Sa ESA, Rocha R, Marinhas J, Freitas R, Guerra-Gomes S, Ferreirinha F, Costa MA & Correia-de-Sa P 2014 P2X7- induced zeiosis promotes osteogenic differentiation and mineralization of postmenopausal bone marrow-derived mesenchymal stem cells. FASEB Journal 28 5208–5222. (doi:10.1096/fj.14-257923)
81. North RA 2002 Molecular physiology of P2X receptors. Physiological Reviews 82 1013–1067. (doi:10.1152/physrev.00015.2002)
82. Ohlendorff SD, Tofteng CL, Jensen JE, Petersen S, Civitelli R, Fenger M, Abrahamsen B, Hermann AP, Eiken P & Jorgensen NR 2007 Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenetics and Genomics 17 555–567. (doi:10.1097/FPC.0b013e3280951625)
83. Okumura H, Shiba D, Kubo T & Yokoyama T 2008 P2X7 receptor as sensitive flow sensor for ERK activation in osteoblasts. Biochemical and Biophysical Research Communications 372 486–490. (doi:10.1016/j.bbrc2008.05.066)
84. Orriss IR, Knight GE, Ranasinghe S, Burnstock G & Arnett TR 2006 Osteoblast responses to nucleotides increase during differentiation. Bone 39 300–309. (doi:10.1016/j.bone.2006.02.063)
85. Orriss IR, Utting JC, Brandao-Burch A, Colston K, Grubb BR, Burnstock G & Arnett TR 2007 Extracellular nucleotides block bone mineralization in vitro: evidence for dual inhibitory mechanisms involving both P2Y2 receptors and pyrophosphate. Endocrinology 148 4208–4216. (doi:10.1210/en.2007-0066)
86. Orriss IR, Knight GE, Utting JC, Taylor SE, Burnstock G & Arnett TR 2009 Hypoxia stimulates vesicular ATP release from rat osteoblasts. Journal of Cellular Physiology 220 155–162. (doi:10.1002/jcp.21745)
87. Orriss IR, Burnstock G & Arnett TR 2010 Purinergic signalling and bone remodelling. Current Opinion in Pharmacology 10 322–330. (doi:10.1016/j.coph.2010.01.003)
88. Orriss IR, Wang N, Burnstock G, Arnett TR, Gartland A, Robaye B & Boeynaems JM 2011 The P2Y(6) receptor stimulates bone resorption by osteoclasts. Endocrinology 152 3706–3716. (doi:10.1210/en.2011-1073)
89. Orriss IR, Key ML, Brandao-Burch A, Patel JJ, Burnstock G & Arnett TR 2012 The regulation of osteoblast function and bone mineralization by extracellular nucleotides: the role of p2x receptors. Bone 51 389–400. (doi:10.1016/j.bone.2012.06.013)
90. Orriss IR, Key ML, Hajjawi MO & Arnett TR 2013 Extracellular ATP released by osteoblasts is a key local inhibitor of bone mineralization. PLoS ONE 8 e69057. (doi:10.1371/journal.pone.0069057)
91. Paneesha S, Starczynski J, Pepper C, Delgado J, Hooper L, Fegan C & Pratt G 2006 The P2X7 receptor gene polymorphism 1513 A/C has no effect on clinical prognostic markers and survival in multiple myeloma. Leukemia & Lymphoma 47 281–284. (doi:10.1080/10428190500305901)
92. Panupinthu N, Zhao L, Possmayer F, Ke HZ, Sims SM & Dixon SJ 2007 P2X7 nucleotide receptors mediate blebbing in osteoblasts through a pathway involving lysophosphatidic acid. Journal of Biological Chemistry 282 3403–3412. (doi:10.1074/jbc.M605620200)
93. Panupinthu N, Rogers JT, Zhao L, Solano-Flores LP, Possmayer F, Sims SM& Dixon SJ 2008 P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. Journal of Cell Biology 181 859–871. (doi:10.1083/jcb.200708037)
94. Pelegrin P & Surprenant A 2006 Pannexin-1 mediates large pore formation and interleukin-1b release by the ATP-gated P2X7 receptor. EMBO Journal 25 5071–5082. (doi:10.1038/sj.emboj.7601378)
95. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V & Di Virgilio F 2008 Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE 3 e2599. (doi:10.1371/journal.pone.0002599)
96. Pellegatti P, Falzoni S,Donvito G, Lemaire I&DiVirgilio F 2011 P2X7receptor drives osteoclast fusion by increasing the extracellular adenosine concentration. FASEB Journal 25 1264–1274. (doi:10.1096/fj.10-169854)
97. Pereverzev A, Komarova SV, Korcok J, Armstrong S, Tremblay GB, Dixon SJ & Sims SM2008 Extracellular acidification enhances osteoclast survival through an NFAT-independent, protein kinase C-dependent pathway. Bone 42 150–161. (doi:10.1016/j.bone.2007.08.044)
98. Qureshi OS, Paramasivam A, Yu JC & Murrell-Lagnado RD 2007 Regulation of P2X4 receptors by lysosomal targeting, glycan protection and exocytosis. Journal of Cell Science 120 3838–3849. (doi:10.1242/jcs.010348)
99. Rapaport E 1983 Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle. Journal of Cellular Physiology 114 279–283. (doi:10.1002/jcp.1041140305)
100. Rassendren F, Buell GN, Virginio C, Collo G, North RA & Surprenant A 1997 The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. Journal of Biological Chemistry 272 5482–5486. (doi:10.1074/jbc.272.9.5482)
101. Reyes JP, Sims SM & Dixon SJ 2011 P2 receptor expression, signaling and function in osteoclasts. Frontiers in Bioscience 3 1101–1118. (doi:10.2741/214)
102. Roger S, Gillet L, Baroja-Mazo A, Surprenant A& Pelegrin P 2010 C-terminal calmodulin-binding motif differentially controls human and rat P2X7 receptor current facilitation. Journal of Biological Chemistry 285 17514–17524. (doi:10.1074/jbc.M109.053082)
103. Rumney RM, Wang N & Gartland A 2010 The role of P2X (7) receptors in ATP release from osteoblasts. In Purinergic Signalling, pp 129–129. Springer.
104. Rumney RMH, Agrawal A, Shah K & Gartland A 2011 Fluid flow stimulates ATP release from human derived osteoclasts without changing resorption. Conference Abstract: 2011 Joint meeting of the Bone Research Society & the British Orthopaedic Research Society. Frontiers in Endocrinology. (doi:10.3389/conf.fendo.2011.02.00056)
105. Rumney RM, Sunters A, Reilly GC & Gartland A 2012a Application of multiple forms of mechanical loading to human osteoblasts reveals increased ATP release in response to fluid flow in 3D cultures and differential regulation of immediate early genes. Journal of Biomechanics 45 549–554. (doi:10.1016/j.jbiomech.2011.11.036)
106. Rumney RMH, Wang N, Agrawal A & Gartland A 2012b Purinergic signalling in bone. Frontiers in Endocrinology 3 116. (doi:10.3389/fendo.2012.00116)
107. Schafer R, Sedehizade F, Welte T & Reiser G 2003 ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. American Journal of Physiology. Lung Cellular and Molecular Physiology 285 L376–L385. (doi:10.1152/ajplung.00447.2002)
108. Shabbir M & Burnstock G 2009 Purinergic receptor-mediated effects of adenosine 50-triphosphate in urological malignant diseases. International Journal of Urology 16 143–150. (doi:10.1111/j.1442-2042.2008.02207.x)
109. Sivaramakrishnan V & Fountain SJ 2012 A mechanism of intracellular P2X receptor activation. Journal of Biological Chemistry 287 28315–28326. (doi:10.1074/jbc.M112.372565)
110. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ & Gabel CA 2001 Altered cytokine production in mice lacking P2X(7) receptors. Journal of Biological Chemistry 276 125–132. (doi:10.1074/jbc.M006781200)
111. Stokes L & Surprenant A 2009 Dynamic regulation of the P2X4 receptor in alveolar macrophages by phagocytosis and classical activation. European Journal of Immunology 39 986–995. (doi:10.1002/eji.200838818)
112. Sun D, Junger WG, Yuan C, Zhang W, Bao Y, Qin D, Wang C, Tan L, Qi B, Zhu D et al. 2013 Shockwaves induce osteogenic differentiation of human mesenchymal stem cells through ATP release and activation of P2X7 receptors. Stem Cells 31 1170–1180. (doi:10.1002/stem.1356)
113. Syberg S, Petersen S, Beck Jensen JE, Gartland A, Teilmann J, Chessell I, Steinberg TH, Schwarz P & Jorgensen NR 2012a Genetic background strongly influences the bone phenotype of P2X7 receptor knockout mice. Journal of Osteoporosis 2012 391097. (doi:10.1155/2012/391097)
114. Syberg S, Schwarz P, Petersen S, Steinberg TH, Jensen JE, Teilmann J & Jorgensen NR 2012b Association between P2X7 receptor polymorphisms and bone status in mice. Journal of Osteoporosis 2012 637986. (doi:10.1155/2012/637986)
115. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J et al. 2002 Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Developmental Cell 3 889–901. (doi:10.1016/S1534-5807(02)00369-6)
116. Thimm D, Knospe M, Abdelrahman A, Moutinho M, Alsdorf BB, von Kugelgen I, Schiedel AC & Muller CE 2013 Characterization of new G protein-coupled adenine receptors in mouse and hamster. Purinergic Signalling 9 415–426. (doi:10.1007/s11302-013-9360-9)
117. Toulme E, Garcia A, Samways D, Egan TM, Carson MJ & Khakh BS 2010 P2X4 receptors in activated C8-B4 cells of cerebellar microglial origin. Journal of General Physiology 135 333–353. (doi:10.1085/jgp.200910336)
118. Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gang AO, Holmstrom M, Gregersen H, Vogel U, Schwarz P et al. 2014 Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma. European Journal of Haematology 93 172–174. (doi:10.1111/ejh.12353)
119. Verkhratsky A & Burnstock G 2014 Biology of purinergic signalling: its ancient evolutionary roots, its omnipresence and its multiple functional significance. BioEssays 36 697–705. (doi:10.1002/bies.201400024)
120. Virginio C, MacKenzie A, North RA & Surprenant A 1999 Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2X7 receptor. Journal of Physiology 519 335–346. (doi:10.1111/j.1469-7793.1999.0335m.x)
121. Volonte C, Apolloni S, Skaper SD & Burnstock G 2012 P2X7 receptors: channels, pores and more. CNS & Neurological Disorders Drug Targets 11 705–721. (doi:10.2174/187152712803581137)
122. Wang L, Jacobsen SE, Bengtsson A & Erlinge D 2004a P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34C stem and progenitor cells. BMC Immunology 5 16. (doi:10.1186/1471-2172-5-16)
123. Wang Q, Wang L, Feng YH, Li X, Zeng R & Gorodeski GI 2004b P2X7 receptor-mediated apoptosis of human cervical epithelial cells. American Journal of Physiology. Cell Physiology 287 C1349–C1358. (doi:10.1152/ajpcell.00256.2004)
124. Wesselius A, Bours MJ, Henriksen Z, Syberg S, Petersen S, Schwarz P, Jorgensen NR, van Helden S & Dagnelie PC 2013 Association of P2X7 receptor polymorphisms with bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients. Osteoporosis International 24 1235–1246. (doi:10.1007/s00198-012-2059-x)
125. White N, Ryten M, Clayton E, Butler P & Burnstock G 2005 P2Y purinergic receptors regulate the growth of human melanomas. Cancer Letters 224 81–91. (doi:10.1016/j.canlet.2004.11.027)
126. Wilson HL, Wilson SA, Surprenant A & North RA 2002 Epithelial membrane proteins induce membrane blebbing and interact with the P2X7 receptor C terminus. Journal of Biological Chemistry 277 34017–34023. (doi:10.1074/jbc.M205120200)
127. Yoshida K, Oida H, Kobayashi T, Maruyama T, Tanaka M, Katayama T, Yamaguchi K, Segi E, Tsuboyama T, Matsushita M et al. 2002 Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. PNAS 99 4580–4585. (doi:10.1073/pnas.062053399)
128. Zheng LM, Zychlinsky A, Liu CC, Ojcius DM & Young JDE 1991 Extracellular Atp as a trigger for apoptosis or programmed cell-death. Journal of Cell Biology 112 279–288. (doi:10.1083/jcb.112.2.279)
129. Zippel N, Limbach CA, Ratajski N, Urban C, Luparello C, Pansky A, Kassack MU & Tobiasch E 2012 Purinergic receptors influence the differentiation of human mesenchymal stem cells. Stem Cells and Development 21 884–900. (doi:10.1089/scd.2010.0576)